<H1> Acino </H1> |
<H1> National Spine & Pain Centers </H1> |
<H1> Acino </H1> |
<H2> Investing to Advance Outcomes
Avista invests in leading healthcare companies to drive growth and build lasting value. Our sector focus, operational insights and flexible capital solutions enable us to provide owners, management teams and investors access to opportunity within a dynamic and diverse industry.
Avista is affiliated with Avista Public Acquisition Corp II, a special purpose acquisition company sponsored by Avista to acquire healthcare companies.
</H2> |
<H2> Investing to Advance Outcomes
Avista invests in leading healthcare companies to drive growth and build lasting value. Our sector focus, operational insights and flexible capital solutions enable us to provide owners, management teams and investors access to opportunity within a dynamic and diverse industry.
Avista is affiliated with Avista Public Acquisition Corp II, a special purpose acquisition company sponsored by Avista to acquire healthcare companies.
</H2> |
<H2> Investing to Advance Outcomes
Avista invests in leading healthcare companies to drive growth and build lasting value. Our sector focus, operational insights and flexible capital solutions enable us to provide owners, management teams and investors access to opportunity within a dynamic and diverse industry.
Avista is affiliated with Avista Public Acquisition Corp II, a special purpose acquisition company sponsored by Avista to acquire healthcare companies.
</H2> |
<H3> Investing to Advance Outcomes </H3> |
<H3> Investing to Advance Outcomes </H3> |
<H3> Investing to Advance Outcomes </H3> |
<H3> About </H3> |
<H3> Latest News </H3> |
<H3> Approach </H3> |
<H3> Team </H3> |
<H3> Portfolio </H3> |
<H3> Responsibility </H3> |
<H3> News </H3> |
<H3> Contact </H3> |
<H4> Avista Capital Partners Announces Leadership Transition, New Partners and Promotions </H4> |
<H4> Avista Public Acquisition Corp. II Completes $230,000,000 Initial Public Offering </H4> |
<H4> Avista Public Acquisition Corp. II Announces Pricing of $200 Million Initial Public Offering </H4> |
<H4> Avista Capital Partners To Sell Arcadia Consumer Healthcare, Inc. To Bansk Group </H4> |
<H4> Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC </H4> |
<H4> Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder </H4> |
<H4> Vision Healthcare announces the acquisition of Sensilab </H4> |
<H4> XIFIN CEO Lâle White Feature in Medical Laboratory Observer </H4> |
<H4> Acino completes acquisition of select portfolio of prescription pharmaceutical products and food supplements from IlmixGroup group of companies in Russia </H4> |
<H4> Avista Capital Makes Investment in eMolecules </H4> |
<H4> Thompson Dean </H4> |
<H4> David Burgstahler </H4> |
<H4> Robert Girardi </H4> |
<H4> Sriram Venkataraman </H4> |
<H4> Greg Cowan </H4> |
<H4> Dr. Rob DeWit </H4> |
<H4> Charles Harwood </H4> |
<H4> William E. Klitgaard </H4> |
<H4> Sam Leno </H4> |
<H4> Brian Markison </H4> |
<H4> Robert O’Neil </H4> |
<H4> Steve Schiess </H4> |
<H4> Joshua Tamaroff </H4> |
<H4> Alex Yu </H4> |
<H4> Zach Kushner </H4> |
<H4> Garrett Lustig </H4> |
<H4> Akbar Mirza </H4> |
<H4> Ryan Moran </H4> |
<H4> Beibhinn George </H4> |
<H4> Will Sauser </H4> |
<H4> Samson Soon </H4> |
<H4> Eddie Zhao </H4> |
<H4> Ben Silbert </H4> |
<H4> John Cafasso </H4> |
<H4> Amanda Heravi </H4> |
<H4> Anthony Russo </H4> |
<H4> Roshni Charles </H4> |
<H4> Melissa Imperiale </H4> |
<H4> Hector Cortes </H4> |
<H4> Max Dooley </H4> |
<H4> Avista Capital Partners Announces Leadership Transition, New Partners and Promotions </H4> |
<H4> Avista Public Acquisition Corp. II Completes $230,000,000 Initial Public Offering </H4> |
<H4> Avista Public Acquisition Corp. II Announces Pricing of $200 Million Initial Public Offering </H4> |
<H4> Avista Capital Partners To Sell Arcadia Consumer Healthcare, Inc. To Bansk Group </H4> |
<H4> Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC </H4> |
<H4> Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder </H4> |
<H4> Vision Healthcare announces the acquisition of Sensilab </H4> |
<H4> XIFIN CEO Lâle White Feature in Medical Laboratory Observer </H4> |
<H4> Terms of Use </H4> |
<H4> Privacy Policy </H4> |
<H5> Partners </H5> |
<H5> Operating Executives </H5> |
<H5> Investment Professionals </H5> |
<H5> Business Management Team </H5> |
Social
Social Data
Cost and overhead previously rendered this semi-public form of communication unfeasible.
But advances in social networking technology from 2004-2010 has made broader concepts of sharing possible.